Synergic effects of ultrasound and laser therapies on mesentery for management of obesity and diabetes in rats

Paolillo, Fernanda Rossi; Campos, Thays Yara Teófilo Borges; Álvarez, Carolina; Sene-Fiorese, Marcela; Bagnato, Vanderlei Salvador; Duarte, Ana Cláudia Garcia de Oliveira; Parizotto, Nivaldo Antônio

doi:10.1002/jbio.202100109

Cited by 4 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge this is the first study to provide convincing evidence using a randomized, double‐blind, crossover and sham‐controlled clinical trial, of the beneficial effects and the dose–response and time–response effects of PBMt, combined or not with the use of oral hypoglycemic medication, on the glycemic control in T2DM patients. Previous studies from our group [33, 34, 53] and from others [30–32, 35, 54, 55] have suggested PBMt could improve glycemic control in insulin resistant T2DM in animal models, however clinical studies on humans are only beginning to emerge.…”

Section: Discussionmentioning

confidence: 99%

Dose and time–response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients combined or not with hypoglycemic medicine: A randomized, crossover, double‐blind, sham‐controlled trial

Scontri,

de Castro Magalhães,

Damiani

et al. 2023

Journal of Biophotonics

View full text Add to dashboard Cite

Photobiomodulation therapy (PBMt) combined or not with oral hypoglycemic medication has not been investigated in type 2 diabetes (T2DM) patients. All 10 T2DM patients were assessed randomly at 6 different occasions (3 with and 3 without regular oral hypoglycemic medication). Capillary glycemia was assessed after overnight fast (pre‐prandial), 1 h postprandially (standardized meal, 338 kcal), and 30 min, 3 h, 6 h, 12 h post‐PBMt (830 nm; 25 arrays of LEDs, 80 mW/array). Three doses (0 J—sham, 100 J, 240 J per site) were applied bilaterally on quadriceps femoris muscles, hamstrings, triceps surae, ventral upper arm and forearm; and randomly combined or not with oral hypoglicemic medication, totaling six different therapies applied for all 10 TDM2 patients (PBMt sham, PBMt 100 J, PBMt 240 J, PBMt sham + medication, PBMt 100 J + medication, PBMt 240 J + medication). Cardiac autonomic control was assessed by heart rate variability (HRV) indices. Without medication, there was reduction in glycemia after all PBMt doses, with 100 J as the best dose that persisted until 12 h and presented lower area under the curve (AUC). With medication, glycemia decreased similarly among doses. No differences between 100 J and sham + medication, but AUC was significantly lower after 100 J, suggesting better glycemic control. Low frequency component of HRV increased after sham + medication and 100 J, suggesting higher sympathetic activation. PBMt showed time– and dose–response effect to reduce glycemia in T2DM patients. Effects on HRV were consistent with glycemic control.

show abstract

Section: Discussionmentioning

confidence: 99%